Summary of the HOMAGE Trial Findings
The HOMAGE trial aimed to understand how diabetes (DM) and coronary artery disease (CAD) affect heart health and how the medication spironolactone can help. The study included 495 participants, mostly older adults, and looked at heart function and specific blood markers over 9 months.
Key Findings
Participants with diabetes, whether they had CAD or not, showed:
- Lower levels of a protein linked to heart tissue (collagen).
- Smaller heart sizes during key phases of the heartbeat.
- Higher levels of certain markers that indicate inflammation and heart stress (galectin-3 and GDF-15).
- Changes in heart function that can lead to heart failure.
The trial found that spironolactone did not significantly change the heart measurements or blood markers across different groups, except for a noticeable reduction in GDF-15 in those with both diabetes and CAD after one month.
Practical Healthcare Results
Identifying Health Changes
Diabetes significantly impacts heart health, regardless of CAD presence. Recognizing these changes early can help in managing risks for heart failure.
Setting Clear Goals
Clinics should aim to:
- Regularly monitor echocardiographic and biomarker changes in patients with diabetes and CAD.
- Implement strategies to reduce inflammation and improve heart function.
Using AI Tools for Better Management
Choose AI solutions that help track heart health metrics and predict outcomes based on echocardiographic and biomarker data from the HOMAGE trial.
Step-by-Step Implementation
Start with a small pilot project to test AI solutions, monitor the results, and expand based on what works best for improving heart health in patients with diabetes and CAD.
Contact Us for AI Solutions in Medical Management
For more information, reach out to us on:
- Telegram: https://t.me/itinai
- X: https://x.com/vlruso
- LinkedIn: https://www.linkedin.com/company/itinai/
